Manage Your Liver
Q:

WHO’s latest Hepatitis strategies are focused on preventing and reducing damage caused by hepatitis, what should hepatitis B and C patients do?

A:

According to the latest data provided by the World Health Organization, there are 400 million people living with hepatitis B and C worldwide; 1.4 million die due to these infections every year and many more become newly infected. [1] In recent years, WHO launched a range of new strategies and guidelines for this serious global problem. In 2014 and 2015, for the first time, WHO introduced countermeasures guidance to countries around the world on hepatitis C and B respectively. In the guidelines, WHO clearly presented a 3-part prevention plan which included (not limited to) the following [2]:

 

  • immunization with the hepatitis A and B vaccines to prevent co-infection from these hepatitis viruses to protect the liver;
  • early and appropriate medical management including antiviral therapy if appropriate; and
  • regular monitoring for early diagnosis of chronic liver disease (including liver cirrhosis and liver cancer)

 

Another document published by WHO – “Prevention and Control of Viral Hepatitis Infection” further states that our goals should be to reduce morbidity and mortality due to viral hepatitis, improve the care of patients with viral hepatitis and improve the support provided by our society to hepatitis patients. [3] This implies that WHO is recommending hepatitis patients to think further; other than just killing the virus, focus should also be put on these aspects: how to avoid the spread of the virus, how to reduce liver damage caused by the virus, how to prevent liver cirrhosis and liver cancer, and how to improve activity and ability to work.

 

In a sense, it also shows that WHO does not consider the effects of current treatment options on viral hepatitis B and C to be ideal. These treatments advocated by various professionals failed to address the hazards of viral hepatitis B and C, prevent new infections, and lower the number of patients, or the number of deaths caused by the disease. However, countries around the world have paid a very high price because of these ineffective methods.

 

For now, the general consensus is that our focus should be put on: preventing new infections and reducing the spread of the virus, advocating and seeking ways to reduce inflammation and damage caused by hepatitis, preventing inflammation in the liver to reduce risks of liver cirrhosis and liver cancer, and improving the everyday ability and life skills of hepatitis patients.

 

In this context, our liver health maintenance methods that we advocate and promote are very much in line with the proposal and conclusions by WHO.

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
A:
About 2.7 million persons in the United States are infected with hepatitis C virus in their blood. The majority of these individuals remain asymptomatic for many years following the initial infection, and many people can even live their whole life with hepatitis C virus in their body without knowing they are infected. On the other hand, some carriers will develop chronic hepatitis C, meaning that the virus in their body attacks the liver, causing liver damage with elevated alan
A:
Since the introduction of direct-acting antiviral (DAA) therapy, treatment for hepatitis C (HCV) was revolutionized, as patient outcomes are improved with fewer side effects and high cure rate. However, there is significant debate in the society based on studies that suggest HCV cure does not eliminate risk for hepatocellular carcinoma (HCC) or liver cancer. Other research suggests the possibility of increased risk of developing liver cancer during and after DAA treatment in patients with hep
Hit Questions
A:
Fibrosis is scarring of the liver that results from chronic inflammation. It is a process where the damaged, dying liver cells are replaced by fibrous scar tissue, causing the liver to become hard. The extent of liver fibrosis can vary, and it is often classified in several stages. The most common classification is a scale from F0 to F4. F0 indicates no fibrosis. A normal liver is at a stage between F0 and F1. F2 denotes light fibrosis, and F3 indicates severe fibrosis. When scar tissue build
A:
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
A:
ALT (Alanine Aminotransferase / SGPT) is an enzyme that is mainly found in liver cells. The level of ALT in our bloodstream is the primary indicator of liver health.   What does high ALT indicate? ALT enzymes are normally contained within liver cells when the liver is healthy, but when the liver cells are injured or damaged by whatever means, ALT enzymes are released into the bloodstream, causing levels to go up. Therefore, by measuring the
A:
Hepatitis C is a wide spread and deadly disease affecting an estimated of 3.5 million Americans.   Treatment for hepatitis C has evolved over the years, going from highly toxic drugs involving injections with horrible side effects, to medications with minimal side effects. Success rate of treatment options has also improved greatly Although the high price tag of the new DAA treatment is controversial, it has undoubtedly helped to cure many hepatitis C patients.
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us